


# Managing Severe or Resistant Hypercholesterolemia

## The Next Generation of LDL-C Lowering Agents

A CME-certified Program



### Program Overview

New and emerging treatments to reduce low-density lipoprotein cholesterol (LDL-C) offer additional options to control cardiovascular disease (CVD) risk in patients who have severe or resistant hypercholesterolemia. There are a number of newly approved and emerging approaches which may be suitable for monotherapy or add-on therapy with statins. These include inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibition of microsomal triglyceride transfer protein (MTP), and inhibition of apolipoprotein B-100 (apo-B) production.

This CME activity, “**Managing Severe and Resistant Hypercholesterolemia**,” will aid participating clinicians in applying evidence-based guidelines to appropriately manage their dyslipidemic patients who are at high risk for adverse cardiovascular events.

### Case Consult

Submit your challenging cardiology case to the faculty to receive expert opinions and recommendations on management choices at this program. Email it to [jgold@rockpointe.com](mailto:jgold@rockpointe.com) 24-48 hours prior to the program start. All case information will be kept confidential and presented anonymously.



### Agenda

Welcome & Introduction  
Treatment Guidelines and Pivotal Clinical Trial Data  
Residual CVD Risk Despite Intensive Statin Therapy  
Adjuncts/Alternatives to Statins to Lower LDL-C and Reduce Residual CVD Risk  
Case Consult, Q&A Session and Activity Roundup

### Target Audience

This activity is intended for community-based cardiologists, internal medicine specialists, and other healthcare providers who manage severely dyslipidemic patients at high risk for adverse cardiovascular events.

### Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

- Describe the consequences of directing moderate to intense statin treatment to identified at-risk populations, rather than treating to LDL-C target goals
- Evaluate extent of residual CVD risk to which high-risk dyslipidemic patients are exposed, and alter prescribing behavior to address additional CVD risk elements as appropriate
- Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk with new LDL-C lowering agents as stand-alone treatments or in combination with statins

### STEERING COMMITTEE

#### Michael Miller, MD, FACC, FAHA

Professor of Cardiovascular Medicine  
Epidemiology and Public Health  
University of Maryland School of Medicine  
Staff Physician, Baltimore VAMC  
Director, Center for Preventive Cardiology  
University of Maryland Medical Center  
Baltimore, MD

#### Peter P. Toth, MD, PhD

Director of Preventative Cardiology  
CGH Medical Center  
Sterling, IL  
Professor of Clinical Family and Community Medicine  
University of Illinois College of Medicine  
Peoria, IL  
Professor of Clinical Medicine  
Michigan State University College of Osteopathic Medicine  
East Lansing, MI  
Adjunct Associate Professor Medicine  
Johns Hopkins University School of Medicine  
Baltimore, MD

**Accreditation** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement** The Potomac Center for Medical Education designates this activity for a maximum of 1.0 *AMA PRA Category I Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email [contact@potomacme.org](mailto:contact@potomacme.org).

**Disclosure Information** Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

**Method of Participation** To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. There are no fees associated with this program.

**Special Services** Event staff will be glad to assist you with any special needs (e.g. physical, dietary, etc.). Please email [specialservices@rockpointe-pcme.com](mailto:specialservices@rockpointe-pcme.com) at least 5 days prior to the program.